← All trials
NCT05940493
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2023
- Primary completion
- Jun 30, 2031
- Completion date
- Dec 31, 2031
- First posted
- Jul 11, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ArizonaLead sponsor
- Eli LillyCollaborator
- University of ArizonaSponsor investigator
- Barrow Neurological InstituteCollaborator
- Ivy Brain Tumor CenterCollaborator
- Ivy Brain Tumor CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.